title: The E-cadherin (CDH1)--160 C/A polymorphism and prostate cancer risk: a meta-analysis.
abstract: Published data on the association between E-cadherin (CDH1) -160 C/A polymorphism and prostate cancer (PCA) risk are inconclusive. To derive a more precise estimation of the relationship, a meta-analysis was performed. A logistic regression approach proposed for molecular association studies was used to estimate a biological model of the gene effect. A total of 11 studies including 2637 cases and 2673 controls were involved in this meta-analysis. Logistic regression analysis indicated that the CDH1 -160 C/A genotypes were associated with PCA risk. The genetic model test indicated that the genetic model was most likely to be dominant (CA+AA vs CC). Overall, meta-analysis indicated that the -160A allele carriers (CA+AA) had a 21% elevated risk of PCA, when compared with the homozygotes (CC) (odds ratio (OR)=1.21; 95% confidence interval (CI): 0.97-1.51; P=0.090, P(heterogeneity)=0.001). In the subgroup analyses by ethnicity, significantly elevated risks were associated with -160 variant genotypes (CA+AA) in both European and Asian populations (OR=1.24; 95% CI: 1.08-1.43; P=0.003, P(heterogeneity)=0.220 and OR=1.54; 95% CI: 1.23-1.93; P<0.001, P(heterogeneity)=0.200). However, no significant associations were found in Africans (OR=0.59; 95% CI: 0.32-1.09; P=0.090, P(heterogeneity)=0.070). Although some modest bias could not be eliminated, this meta-analysis suggests that the CDH1 -160A allele is a low-penetrant risk factor for developing PCA, especially in Europeans and Asians.
authors.affiliation: Cancer Center, Nanjing Drum Tower Hospital, Nanjing Medical University, Nanjing, China.
authors.forename: Li-Xin
authors.initials: LX
authors.lastname: Qiu
authors.forename: Ru-Tian
authors.initials: RT
authors.lastname: Li
authors.forename: Jian-Bing
authors.initials: JB
authors.lastname: Zhang
authors.forename: Wen-Zhao
authors.initials: WZ
authors.lastname: Zhong
authors.forename: Jian-Ling
authors.initials: JL
authors.lastname: Bai
authors.forename: Bao-Rui
authors.initials: BR
authors.lastname: Liu
authors.forename: Ming-Hua
authors.initials: MH
authors.lastname: Zheng
authors.forename: Xiao-Ping
authors.initials: XP
authors.lastname: Qian
mesh_terms: D015820:Cadherins / Q000235:genetics*; D020022:Genetic Predisposition to Disease; D006801:Humans; D016015:Logistic Models; D008297:Male; D011110:Polymorphism, Genetic; D011471:Prostatic Neoplasms / Q000235:genetics*
chemical_list: D015820:Cadherins
references.citation: Jpn J Clin Oncol. 2005 Mar;35(3):158-61
references.pmid: 15741307
references.citation: Cancer Cell Int. 2003 Oct 14;3(1):17
references.pmid: 14613514
references.citation: Genet Med. 2002 Mar-Apr;4(2):45-61
references.pmid: 11882781
references.citation: Int J Cancer. 2004 Apr 10;109(3):348-52
references.pmid: 14961571
references.citation: Int J Cancer. 2002 Aug 20;100(6):683-5
references.pmid: 12209606
references.citation: N Engl J Med. 2000 Jul 13;343(2):78-85
references.pmid: 10891514
references.citation: Hum Genet. 2005 Dec;118(3-4):339-47
references.pmid: 16189707
references.citation: Science. 1991 Mar 22;251(5000):1451-5
references.pmid: 2006419
references.citation: J R Soc Promot Health. 2004 Sep;124(5):219-21
references.pmid: 15493781
references.citation: J Urol. 2006 Aug;176(2):793-6
references.pmid: 16813949
references.citation: Cancer. 2002 Mar 1;94(5):1443-8
references.pmid: 11920500
references.citation: Cancer Res. 1994 Jul 15;54(14):3929-33
references.pmid: 7518346
references.citation: Ann Hum Genet. 1955 Jun;19(4):251-3
references.pmid: 14388528
references.citation: Trends Genet. 2004 Sep;20(9):439-44
references.pmid: 15313553
references.citation: Hum Mutat. 1998;12(4):226-37
references.pmid: 9744472
references.citation: Mutat Res. 2002 May 22;502(1-2):19-24
references.pmid: 11996968
references.citation: J Natl Cancer Inst. 2004 Mar 17;96(6):434-42
references.pmid: 15026468
references.citation: Cancer Lett. 2003 May 30;195(1):53-8
references.pmid: 12767511
references.citation: Stat Med. 2005 May 15;24(9):1291-306
references.pmid: 15568190
references.citation: Cancer Res. 2000 Feb 15;60(4):873-6
references.pmid: 10706097
references.citation: Endocr Relat Cancer. 2003 Jun;10(2):225-59
references.pmid: 12790786
references.citation: Urol Int. 2004;72(3):203-7
references.pmid: 15084762
references.citation: World J Urol. 2004 Feb;21(6):414-23
references.pmid: 14648103
references.citation: Int J Cancer. 2004 Apr 10;109(3):480-1
references.pmid: 14961592
references.citation: Urology. 2007 Jul;70(1):127-30
references.pmid: 17656222
references.citation: BJU Int. 2000 Nov;86(7):869-78
references.pmid: 11069416
references.citation: BMJ. 1997 Sep 13;315(7109):629-34
references.pmid: 9310563
references.citation: Prostate. 2006 Apr 1;66(5):546-56
references.pmid: 16372334
references.citation: Epidemiology. 1997 Nov;8(6):653-7
references.pmid: 9345665